Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling
- 1 July 2006
- journal article
- research article
- Published by Taylor & Francis Ltd in Xenobiotica
- Vol. 36 (7), 567-580
- https://doi.org/10.1080/00498250600761662
Abstract
Previously in vitro–in vivo extrapolation (IVIVE) with the Simcyp Clearance and Interaction Simulator® has been used to predict the clearance of 15 clinically used drugs in humans. The criteria for the selection of the drugs were that they are used as probes for the activity of specific cytochromes P450 (CYPs) or have a single CYP isoform as the major or sole contributor to their metabolism and that they do not exhibit non-linear kinetics in vivo. Where data were available for the clearance of the drugs in at least three animal species, the predictions from IVIVE have now been compared with those based on allometric scaling (AS). Adequate data were available for estimating oral clearance (CLp.o.) in 9 cases (alprazolam, sildenafil, caffeine, clozapine, cyclosporine, dextromethorphan, midazolam, omeprazole and tolbutamide) and intravenous clearance in 6 cases (CLi.v.) (cyclosporine, diclofenac, midazolam, omeprazole, theophylline and tolterodine). AS predictions were based on five different methods: (1) simple allometry (clearance versus body weight); (2) correction for maximum life-span potential (CL × MLP); (3) correction for brain weight (CL × BrW); (4) the use of body surface area; and (5) the rule of exponents. A prediction accuracy was indicated by mean-fold error and the Pearson product moment correlation coefficient. Predictions were considered successful if the mean-fold error was ≤2. IVIVE predictions were accurate in 14 of 15 cases (mean-fold error range: 1.02–4.00). All five AS methods were accurate in 13, 11, 10, 10 and 14 cases, respectively. However, in some cases the error of AS exceeded fivefold. On the basis of the current results, IVIVE is more reliable than AS in predicting human clearance values for drugs mainly metabolized by CYP450 enzymes. This suggests that the place of AS methods in pre-clinical drug development warrants further scrutiny.Keywords
This publication has 85 references indexed in Scilit:
- The Potential for CYP2D6 Inhibition Screening Using a Novel Scintillation Proximity Assay-Based ApproachSLAS Discovery, 2001
- Prediction of Hepatic Metabolic ClearanceClinical Pharmacokinetics, 2001
- Rebuttal to MahmoodThe Journal of Clinical Pharmacology, 2000
- Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo CorrelationsClinical Pharmacokinetics, 1999
- The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I ProtocolsClinical Pharmacokinetics, 1999
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- A Study of the Potential Effect of Sertraline on the Pharmacokinetics and Protein Binding of TolbutamideClinical Pharmacokinetics, 1997
- Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two speciesLife Sciences, 1996
- Pharmacokinetics and bioavailability of diclofenac in the ratJournal of Pharmacokinetics and Biopharmaceutics, 1991
- Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1982